Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded
Category: #healthcare  By Akshay Kedari  Date: 2020-10-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded

Syros Pharmaceuticals has announced initial safety, pharmacodynamics (PD) and pharmacokinetics (PK) data from the current dose-escalation portion of Phase 1 clinical trial of SY-5609 in patients with select solid tumors.

For the starters, SY-5609 is a potent and highly selective oral cyclin-dependent kinase 7 (CDK7) inhibitor. The initial data—set to be revealed in a poster session at the 32nd EORTC-NCI-AACR Symposium—stage an MTD (maximum tolerated dose) for relentless daily dosing and serve as a “proof of mechanism” in patients with advanced solid tumors.

David A. Roth, M.D., Chief Medical Officer of Syros, is buoyed by the findings from Phase 1 trial of SY-5609 and claims that it reinforces their conviction in CDK7 inhibition as a likely transformative targeted approach for difficult-to-treat cancers.

Elaborating on the clinical trial, the Chief Medical Officer said they are “committed to fully exploring the potential of SY-5609.” He further noted that the trial was opened to pancreatic cancer patients; Syros expanded a cohort to emphasize lung cancer patients and further expanded the amalgamation cohort in treatment-resistant breast cancer patients.

In a bid to introduce optimal next steps meant for single-agent and providing the greatest services to patients, Syros has opened cohorts assessing alternate dosing regimens.

The Phase 1 clinical trial will continue to enroll patients with select solid tumors, such as the recently expanded single-agent cohort in lung cancer patients and combination cohort to assess the 3 mg daily dose in patient populations in breast cancer patients.

The trial is alleged to have opened to patients with advanced pancreatic cancer—a tumor that has exhibited sensitivity to SY-5609 in preclinical models.

Syros is slated to report additional dose-escalation data, including Clinical Activity Data in mid-2021. The company claims the safety profile of SY-5609, along with fulvestrant to be in line with single-agent SY-5609.

Source credit:

https://ir.syros.com/press-releases/detail/200/syros-presents-initial-data-from-phase-1-clinical-trial-of

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

GOAT Brand Labs secures USD 36 million in Series A funding round
GOAT Brand Labs secures USD 36 million in Series A funding round
By Akshay Kedari

Apparel-centric platform GOAT Brand Labs has reportedly raised USD 36 million in its first funding r...

Suzuki and Daihatsu planning to join Toyota’s electrification venture
Suzuki and Daihatsu planning to join Toyota’s electrification venture
By Akshay Kedari

Japanese automakers Suzuki Motor Corp. along with Daihatsu Motor Co. Ltd. are joining the commercial...

Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
By Akshay Kedari

Chennai-based aquaculture startup, Aquaconnect has reportedly raised USD 4 million in a pre-Series A...